Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or Female 18 years or older~* Clinically definite diagnosis of Tuberous Sclerosis Complex according to the modified Gomez criteria or sporadic LAM (biopsy-proven or compatible chest CT scan)~* Clinically definite diagnosis of renal angiomyolipoma~* At least one Angiomyolipoma of ≥ 3 cm in its longest diameter using CT or MRI~* Females of child bearing potential must use birth control and have documentation of negative pregnancy test~* Written informed consent according to local guidelines~Exclusion Criteria:~* Recent heart attack, cardiac related chest pain or stroke~* Severely impaired lung function~* Bleeding related to angiomyolipoma or embolization during 6 months prior to randomization~* Clinically significant chylous ascites~* Clinically significant hematological or hepatic abnormality~* Severe liver dysfunction~* Severe kidney dysfunction~* Pregnancy or breast feeding~* Current infection~* History of organ transplant~* Surgery within two months prior to study enrollment~* Prior therapy with a medication in the same class as Everolimus~* Recent use of an investigational drug~* Bleeding diathesis or on oral anti-vitamin K medication~* Uncontrolled high cholesterol~* Uncontrolled diabetes~* HIV~* Inability to attend scheduled clinic visits~* Patients with metal implants thus prohibiting MRI evaluations~* Angiomyolipoma which requires surgery at the time of randomization~* History of malignancy~* Severe or uncontrolled medical conditions which would cause an unacceptable safety risk or compromise compliance with the protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Everolimus (Type: EXPERIMENTAL): Study drug was given by continuous oral daily dosing of two 5 mg tablets.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo was given by continuous oral daily dosing of two 5 mg tablets.

Based on this trial design, predict the completion outcome and termination type (if applicable).